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Introduction: Serum cystatin C can improve glomerular filtration rate (GFR) estimation over creatinine alone, but
whether this translates into clinically relevant improvements in drug dosing is unclear.
Methods: This prospective cohort study enrolled adults receiving scheduled intravenous vancomycin while
hospitalized at the Mayo Clinic in 2012. Vancomycin dosing was based on weight, serum creatinine with the
Cockcroft-Gault equation, and clinical judgment. Cystatin C was later assayed from the stored serum used for the
creatinine-based dosing. Vancomycin trough prediction models were developed by using factors available at
therapy initiation. Residuals from each model were used to predict the proportion of patients who would have
achieved the target trough with the model compared with that observed with usual care.
Results: Of 173 patients enrolled, only 35 (20%) had a trough vancomycin level within their target range (10 to
15 mg/L or 15 to 20 mg/L). Cystatin C-inclusive models better predicted vancomycin troughs than models
based upon serum creatinine alone, although both were an improvement over usual care. The optimal model
used estimated GFR by the Chronic Kidney Disease Epidemiology Collaborative (CKD-EPI) creatinine-cystatin C equation
(R2 = 0.580). This model is expected to yield 54% (95% confidence interval 45% to 61%) target trough attainment
(P <0.001 compared with the 20% with usual care).
Conclusions: Vancomycin dosing based on standard care with Cockcroft-Gault creatinine clearance yielded
poor trough achievement. The developed dosing model with estimated GFR from CKD-EPIcreatinine-cystatin C could
yield a 2.5-fold increase in target trough achievement compared with current clinical practice. Although this
study is promising, prospective validation of this or similar cystatin C-inclusive dosing models is warranted.Introduction
The use of vancomycin, an anti-infective active against
Gram-positive organisms, has increased nearly 100-fold
over the last three decades [1-3]. This surge in utilization
likely reflects the growing prevalence of staphylococcal in-
fections, often methicillin-resistant Staphylococcus aureus
(MRSA), for which vancomycin is considered first-line
therapy [4,5]. Since vancomycin has a narrow therapeutic
window, routine therapeutic drug monitoring with serum
trough concentrations is recommended [4,5]. Unfortunately,* Correspondence: frazee.erin@mayo.edu
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practice fails to reach trough targets in more than 50% of
patients [6].
Although the precise reason for failure to achieve
vancomycin targets is unknown, it may pertain to subopti-
mal assessment of glomerular filtration rate (GFR) be-
cause nearly 90% of the drug is eliminated renally [5,7,8].
The GFR in vancomycin dosing algorithms is most com-
monly estimated by Cockcroft-Gault creatinine clearance
[8-10]. Unfortunately, these dosing algorithms were devel-
oped before serum creatinine assays were standardized.
Also, creatinine-based GFR estimates are influenced by
non-GFR factors not adequately accounted for by adjust-
ments for age, sex, ethnicity, and weight. Finally, rapidLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tured by serum creatinine monitoring [11-19].
Cystatin C is another endogenous biomarker that, in
combination with serum creatinine, improves GFR esti-
mation relative to creatinine alone [12,20-24]. Unfortu-
nately, the literature on cystatin C-guided medication
dosing remains limited [25-31]. Pharmacokinetic ana-
lyses suggest that cystatin C may better predict vanco-
mycin clearance than creatinine, yet the relationship of
this biomarker with steady-state trough levels remains
unclear [26-28]. Furthermore, it is unknown whether the
combination of creatinine and cystatin C can be used to
predict vancomycin troughs better than either GFR
marker used in isolation. The purpose of this study was
to determine the optimal model to predict vancomycin
trough levels using serum creatinine or cystatin C or
both. Results suggest that vancomycin dosing algorithms




This prospective cohort study enrolled hospitalized adults
at the Mayo Clinic in Rochester, Minnesota, who received
intravenous vancomycin between March and October
2012 and had Minnesota research authorization [32]. The
Mayo Clinic Institutional Review Board approved the
protocol and waived the need for informed consent be-
cause the study was considered minimal risk. Other eligi-
bility criteria included the measurement of creatinine
upon vancomycin initiation (enrollment creatinine), avail-
ability of stored serum from this same sample for cystatin
C measurement, and a steady-state vancomycin level. Pa-
tients were excluded if they developed stage 2 or stage 3
acute kidney injury (AKI) at baseline or prior to the
vancomycin level, because changing renal function would
prohibit the achievement of a steady state during vanco-
mycin dosing [33]. In such cases, clinicians routinely ad-
minister a single dose of vancomycin and perform serial
serum concentration monitoring to determine the appro-
priate time for a re-dose. Patients who received vanco-
mycin at an inconsistent dose or interval were also
excluded as were individuals with a body mass index of
greater than 32 kg/m2 due to altered vancomycin pharma-
cokinetics in obesity [34].
Institutionally endorsed vancomycin dosing and moni-
toring recommendations were in place throughout the
study [5,10,11]. Briefly, a vancomycin loading dose of 20
to 30 mg/kg and a maintenance dose of 15 to 20 mg/kg
based on actual body weight were recommended for all
patients. Dosing intervals were informed primarily by the
Cockcroft-Gault creatinine clearance [10,11,35]. Regimens
were tailored by the care team according to severity of in-
fection and other determinants of renal function (that is,urine output), if available. Ultimately, the primary service,
supported by a clinical pharmacist, both without cystatin
C levels, established an individualized vancomycin regi-
men for each patient. In accordance with national guide-
lines, each regimen was designed to achieve a target
vancomycin trough level, either between 10 and 15 mg/L
or between 15 and 20 mg/L, appropriate for the suspected
or documented source(s) of infection [4,5]. Specifically,
individuals with bacteremia, endocarditis, osteomyelitis,
meningitis, or pneumonia with a suspected association
with S. aureus were assigned a goal trough range of 15 to
20 mg/L. In all other cases, the target trough range
assigned was 10 to 15 mg/L. Vancomycin dosing inter-
val reflects GFR and the anticipated drug half-life.
Using guideline recommendations, trough levels were
all drawn immediately before the fourth dose of vanco-
mycin to approximate steady-state conditions (4 to 5
half-lives) [4,5].
Measures
Patient demographics (age, gender, race, and ethnicity),
comorbid conditions, severity of illness, and admission
diagnosis were each noted. Other abstracted data in-
cluded source of infection, vancomycin dose and inter-
val, and routine laboratory data. Vancomycin level was
analyzed by using the Syva Emit® 2000 Vancomycin
Assay (Siemens Healthcare Diagnostics, Inc., Newark,
DE, USA). For the 12 (7%) individuals with undetectable
vancomycin levels (<5.0 mg/L), serum levels were re-
corded as 2.5 mg/L. Creatinine measurement was per-
formed by using the standardized—isotope dilution mass
spectrometry (IDMS) traceable—Roche enzymatic cre-
atinine assay (Roche, Basel, Switzerland). In patients re-
ceiving intravenous catecholamines, known to interfere
with enzymatic assays, an IDMS traceable Roche rate-
Jaffe creatinine assay was used instead (Roche Cobas
Integra 400 Plus chemistry analyzer). Cystatin C was mea-
sured on stored serum used for the enrollment creatinine
with a particle-enhanced turbidimetric assay (Gentian AS,
Moss, Norway). This assay is traceable to the same
international certified cystatin C reference material
(ERM-DA471/IFCC) used to develop the cystatin C-based
Chronic Kidney Disease Epidemiology Collaborative
(CKD-EPI) equations [12,36].
Data analysis
Continuous data were summarized by using mean ±
standard deviation (SD) or median with interquartile
range depending on distribution. The Wilcoxon signed-
rank test was used to detect intra-individual differences
in GFR estimates. Frequencies (percentages) were used
to describe discrete data. The Pearson’s chi-square test
or Fisher’s exact test analyzed independent binary out-
comes between groups, whereas the McNemar’s test was
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tween dosing approaches.
Linear regression was used to develop predictive
models for the vancomycin trough level (Figure 1). To
develop models that would be clinically useful, predic-
tors were included in the model only if readily available
at baseline. Multivariate models included various combi-
nations of age, sex, race, height (centimeters), weight
(kilograms), body mass index (kilograms per square meter),
baseline creatinine (milligrams per deciliter), and baseline
cystatin C (milligrams per liter). Logarithmic transformation
of serum creatinine and cystatin C improved model fit. The
change in creatinine from pre-enrollment to enrollment
(usually a 24-hour interval), total vancomycin dose received
prior to trough (sum of the first three doses), use of a load-
ing dose, dosing interval, and estimated GFR (eGFR) were
also assessed. eGFR was determined by the Cockcroft-Gault
equation and the three CKD-EPI equations (creatinine,
cystatin C, or creatinine and cystatin C) re-expressed
in milliliters per minute by multiplying by body surface
area (BSA) derived from the Du Bois formula divided
by 1.73 m2 [12,37].
The target range for the vancomycin trough (10 to
15 mg/L or 15 to 20 mg/L) was based on the clinical in-
dication for treatment. We analyzed our regression models
to determine how well they would be expected to achieve
vancomycin troughs within target ranges compared with
usual clinical practice. First, model residuals for each pa-
tient were calculated on the basis of the differences be-
tween predicted and observed vancomycin trough levels.
Model residuals represent all the unpredictable variation
in vancomycin trough levels. Then model residualsEnrollment



































Figure 1 Patient enrollment flowchart.were added to the target trough level (either 12.5 if tar-
get trough range was 10 to 15 mg/L or 17.5 if target
trough range was 15 to 20 mg/L) to determine the ex-
pected trough. Thus, the expected trough is based on
both the predictable variation (12.5 or 17.5 mg/L) and
the unpredictable variation (residual) from the regres-
sion model. The proportion of individuals with an ex-
pected trough within their target trough range was
then calculated.
To address potential over-fitting of models for trough
level prediction, cross-validation was performed on the
model with the best fit (highest R2). The final model was
re-derived by using 90% of the sample (n = 156) and vali-
dated in the remaining 10% (n = 17). This cross-validation
was repeated 10 times to determine the mean proportion
of expected levels within the target trough range across
the 10 replications. All analyses were performed with
JMP version 9 statistical software (SAS Institute Inc.,
Cary, NC, USA).
Results
Of the 552 patients screened for eligibility, 173 individ-
uals were enrolled in the study. The majority of excluded
patients lacked an adequate stored specimen for cystatin
C measurement (n = 189), were obese (n = 99), or declined
research authorization for the study (n = 53) (Figure 2). No
patients were excluded for KDIGO (Kidney Disease: Im-
proving Global Outcomes) stage 2 or stage 3 AKI. The
final cohort was 59 ± 16 (mean ± SD) years old, 54% male,
and predominately Caucasian (95%). The mean BSA of in-
cluded patients was 1.86 ± 0.2 m2 with a range of 1.29 to






Adults with intravenous vancomycin, 
a serum trough concentration, and a baseline serum creatinine
(N = 552)
Exclusions
Stored specimen not available (N = 189)
Body mass index > 32 kg/m2 (N = 99)
Denied research authorization (N = 53)
Vancomycin dose, interval or trough 
did not meet study definitions (N = 25)
Not hospitalized (N = 6)
Renal replacement therapy (N = 4)
Sample handling problems (N = 3)
Hospitalized patients with a steady-state vancomycin trough concentration, 
a baseline serum creatinine, and a retrospectively determined baseline serum cystatin C
(N = 173)
Figure 2 Overview of the study protocol. Factors available at baseline, prior to the first vancomycin dose, were used to develop vancomycin
trough level prediction models. Steady-state vancomycin trough adequacy, prior to the fourth dose, was determined according to individualized
target ranges based on suspected or documented source(s) of infection.
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60 mL/min was evident in 20% of patients (Table 1). The
eGFR by CKD-EPIcystatin C was significantly lower than by
CKD-EPIcreatinine (−14 ± 25 mL/min, P <0.001). A creatin-
ine value prior to the study baseline (Figure 1) was avail-
able in 122 (71%) individuals. Using this value, stage 1 AKI
(an at least 0.3 mg/dL creatinine increase from baseline),
though not an explicit exclusion criterion, affected only
four (3%) patients in the included sample. The adminis-
tered vancomycin maintenance dose compared well with
institutional and national guidelines (16.3 ± 2.4 mg/kg).
Dosing frequency differed from the institutional recom-
mendations in 132 (76%) patients, most commonly be-
cause providers selected less frequent dosing intervals. The
target troughs were 10 to 15 mg/L for 40% of patients and
15 to 20 mg/L for 60% of patients.
Univariate analyses demonstrated a significant associ-
ation between steady-state vancomycin trough level and
each of the following variables: log creatinine, log cysta-
tin C, eGFR, and total pre-trough vancomycin dose
(Table 2). All multivariable models included vancomycin
total dose and dosing interval. Separate models were de-
veloped by using the serum kidney function markers
(serum creatinine or cystatin C or both) alone and as
part of each of the four kidney function equations.
Height was removed from the serum kidney function
marker models as it was not a statistically significant
predictor. Owing to the low prevalence of non-Caucasian
race (5%), this predictor was also omitted. Models in-
cluded age, sex, and weight, when not imbedded in GFR
calculations. The models with the best fit and target
trough achievement included cystatin C (Table 3 and
Figure 3). The published CKD-EPI equations reporteGFR in milliliters per minute per 1.73 m2 [12]. Either
converting CKD-EPI eGFR to milliliters per minute or
adding weight improved model fit, but doing both did
not further improve fit (Additional file 1).
The vancomycin trough achieved target in only 35 patients
(20%) during routine clinical care with maintenance doses of
15 to 20 mg/kg and intervals informed by the Cockcroft-
Gault creatinine clearance. Trough achievement in clinical
practice was 22% when institutional dosing interval recom-
mendations were followed compared with 20% when not
followed (P= 0.8). Application of the model with the greatest
power (model 7: eGFR with CKD-EPIcreatinine-cystatin C; R
2 =
0.580) is expected to yield about a 2.5-fold greater trough
achievement than that which resulted from routine clinical
practice (54% versus 20%; P <0.0001 versus observed
trough). Among patients with CKD (defined as CKD-
EPIcreatinine-cystatin C of less than 60 mL/min), the im-
provement between observed and expected trough
achievement was modest (34% versus 43%, P = 0.4). In
contrast, among patients without CKD (defined as
CKD-EPIcreatinine-cystatin C of more than 60 mL/min),
the improvement between observed and expected trough
achievement was much greater (17% versus 57%, P <0.001).
Notably, low trough levels were associated with a high GFR
(Figure 4; P <0.0001). Cross-validation of model 7 to ad-
dress potential overfitting of the data projected a slightly
lower target trough achievement of 51% across the 10
replications instead of 54%.
Discussion
In this study, only 20% of patients achieved a serum
vancomycin trough level within their target range under
usual care based on a combination of the Cockcroft-
Table 1 Baseline patient characteristics, demographics,
and infection characteristics
Characteristic Patients (n = 173)a
Age, years 59 ± 16
Male, n (%) 93 (54)
Caucasian, n (%) 164 (95)
Body mass index, kg/m2 25.5 ± 3.6
Body surface area, m2 1.9 ± 0.2
Non-operative admission diagnosis, n (%) 110 (65)
Intensive care unit, n (%) 37 (22)
Renal parameters
History of moderate to severe kidney
disease, n (%)
22 (13)
Serum creatinine, mg/dLb 0.8 ± 0.4
Cystatin C, mg/L 1.1 ± 0.5
eGFR, mL/minc
Cockcroft-Gault 108 ± 48
CKD-EPIcreatinine 98 ± 29
CKD-EPIcystatin C 84 ± 37
CKD-EPIcreatinine-cystatin C 91 ± 33








Culture positive, n (%) 98 (57)
Monomicrobial 51
Specific Gram-positive organisms isolated
Coagulase-negative Staphylococcus spp. 25
Methicillin-susceptible Staphylococcus aureus 15
Methicillin-resistant S. aureus 10
Enterococcus spp. 22
Vancomycin
Loading dose used, n (%) 64 (37)
Maintenance dose
Non-weight based, mg 1,206 ± 263
Weight-based, mg/kg 16.3 ± 2.4
Dose between 14 and 21 mg/kg, n (%) 152 (88)
Interval, n (%)
8 hours 8 (5)
12 hours 148 (86)
24 hours 17 (10)
Table 1 Baseline patient characteristics, demographics,
and infection characteristics (Continued)
Goal trough according to site of infection
10-15 mg/L, n (%) 69 (40)
15-20 mg/L, n (%) 104 (60)
Trough level, mg/L 12.5 ± 6.0
aValues expressed as mean ± standard deviation unless noted. bTo convert the
values for serum creatinine to micromoles per liter, multiply by 88.4. cTo
convert from mL/min per 1.732 multiply by [(0.007184*height (cm)0.725*weight
(kg)0.425)/1.73] [37]. dSum of percentages exceeds 100 due to multiple sources
of suspected/documented infection. eOther sources include genitourinary,
febrile neutropenia, cardiovascular, central nervous system, acute otitis media,
and prophylaxis. CKD-EPI, Chronic Kidney Disease Epidemiology Collaborative;
eGFR, estimated glomerular filtration rate; n, number.
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judgment. To determine whether clinically available data
could be used to predict trough levels, we developed
novel models based on serum creatinine, cystatin C, or
eGFR with the Cockcroft-Gault and CKD-EPI equations.
The optimal model used the CKD-EPIcreatinine-cystatin C
equation for eGFR and is projected to improve trough
achievement to greater than 50%. When these models
were used, a practical set of dosing recommendations
for vancomycin using the CKD-EPI equations could be
developed for prospective testing.Table 2 Univariate predictors of vancomycin trough level,
mg/L
Potential baseline predictor Beta P value
Demographic and anthropometric data
Age, year 0.057 0.06
Male −0.076 0.97
Height, cm −0.015 0.72
Weight, kg 0.039 0.12
Kidney function markers
Log creatinine, mg/dL 5.320 <0.001
Log cystatin C, mg/L 9.592 <0.001
Equations for estimated GFR, mL/mina
Cockcroft-Gault −0.041 <0.001
CKD-EPIcreatinine −0.076 <0.001
CKD-EPIcystatin C −0.094 <0.001
CKD-EPIcreatinine-cystatin C −0.101 <0.001
Vancomycin parameters
Loading dose given 1.412 0.15
Total pre-trough dose, g 1.635 0.004
Interval
Every 8 hours 2.216 0.33
Every 12 hours REF -
Every 24 hours −0.943 0.56
aTo convert from mL/min per 1.732 multiply by [(0.007184*height (cm)0.725*weight
(kg)0.425)/1.73] [37]. CKD-EPI, Chronic Kidney Disease Epidemiology Collaborative;
GFR, glomerular filtration rate; REF, reference.
Table 3 Predictive models for vancomycin trough level,
mg/L










Age, years 0.0886 0.002
Male −2.30 0.02
Weight, kg −0.0136 0.004
Vancomycin total dose, g 3.28 <0.001
Every 8-hour interval 3.18 0.1
Every 12-hour interval REF -
Every 24-hour interval −6.61 <0.001






Age, years −0.00578 0.8
Male −2.32 0.004
Weight, kg −0.0708 0.05
Vancomycin total dose, g 2.50 <0.001
Every 8-hour interval 4.25 0.009
Every 12-hour interval REF -
Every 24-hour interval −6.66 <0.001







Age, years 0.00582 0.8
Male −2.64 0.001
Weight, kg −0.0931 0.01
Vancomycin total dose, g 2.70 <0.001
Every 8-hour interval 4.15 0.009
Every 12-hour interval REF -
Every 24-hour interval −7.90 <0.001
Log baseline creatinine 2.89 0.01
Log baseline cystatin C 11.3 <0.001





Vancomycin total dose, g 2.66 <0.001
Every 8-hour interval 3.20 0.1
Every 12-hour interval REF -




Table 3 Predictive models for vancomycin trough level,
mg/L (Continued)





Vancomycin total dose, g 3.35 <0.001
Every 8-hour interval 3.47 0.06
Every 12-hour interval REF -









Vancomycin total dose, g 2.61 <0.001
Every 8-hour interval 4.91 <0.001
Every 12-hour interval REF -
Every 24-hour interval −5.94 <0.001
eGFR with CKD-EPIcystatin C,
mL/minb
−0.134 <0.001





Vancomycin total dose, g 2.95 <0.001
Every 8-hour interval 4.84 0.002
Every 12-hour interval REF -





aVancomycin total dose represents the cumulative grams of vancomycin given
prior to trough level being drawn. Per the study definition, this represents three
doses of vancomycin therapy. bTo convert from milliliters per minute per 1.732,
multiply by [(0.007184*height (cm)0.725*weight (kg)0.425)/1.73] [37]. CI, confidence
interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaborative; eGFR,
estimated glomerular filtration rate; REF, reference.
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of the first surrogates of GFR to emerge as a viable and
practical alternative to creatinine in the last several de-
cades [33,38]. Minimal data regarding the use of cystatin
C-based medication dosing have been published. The
present study demonstrated that the use of serum cysta-
tin C, alone or with creatinine, improved expected target
vancomycin trough achievement. Published pharmacoki-
netic analyses also suggest that cystatin C-based GFR es-
timates more accurately predict vancomycin clearance
than creatinine clearance [25,29,30,39]. Furthermore, the
current literature suggests that steady-state vancomycin
troughs correlate more significantly with cystatin C-based
models than creatinine-based models, largely due to re-
duced error among older individuals [26-28]. The present
study demonstrates the potential utility of cystatin C to
Figure 3 Graphical representation of the expected improvement in vancomycin trough target levels with application of the Chronic
Kidney Disease Epidemiology Collaborative models. Predicted trough for each model (x-axis) versus actual trough or versus the expected
trough when targeting 15 mg/L with the model (y-axis) for model 5 (a,b), model 6 (c,d), and model 7 (e,f). The improvement in the proportion
that would have an expected trough of 10 to 20 mg/L for each model is also shown. The more refined analysis targeting a trough of 10 to 15 or
15 to 20 mg/L (depending on the clinical indication for treatment) is presented in the text and tables.
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setting.
Although there is much emphasis on drug dose adjust-
ment for patients with CKD (GFR <60 mL/min), we
found that the greatest improvement in target trough
attainment was among patients without CKD (GFR
>60 mL/min). Indeed, the cystatin C-based models
particularly improved predicted troughs among those
with a GFR of more than 120 mL/min, a group in
whom underdosing frequently occurs under usual clin-
ical care [40]. These findings are similar to those of an-
other recent report which demonstrated that cystatin
C performed better than creatinine clearance for vanco-
mycin dosing when the serum creatinine was not more
than 1.2 mg/dL [39].Our study expands upon previous work because it ac-
counts for other clinically relevant non-GFR factors in
the predictive model, including the use of a vancomycin
loading dose and the total dose given prior to the trough
level. As expected, loading doses were not associated
with predicted vancomycin trough since troughs were
measured under steady-state conditions. Although vanco-
mycin loading has the theoretical pharmacokinetic benefit
of expediting the time to a higher serum drug concentra-
tion and potential clinical effect (not measured in this
study), our study detected no impact of loading on steady-
state blood levels among the 37% of patients in whom one
was used [41]. Drug dosing recommendations by the US
Food and Drug Administration and those used in clinical




















Figure 4 Association between vancomycin trough
concentrations and estimated glomerular filtration rate (GFR)
with CKD-EPIcreatinine-cystatin C. A significant inverse relationship
exists between GFR and vancomycin troughs (P <0.0001). Patients
with a GFR of more than 120 mL/min rarely reached the minimum
acceptable trough of 10 mg/L. CKD-EPI, Chronic Kidney Disease
Epidemiology Collaborative.
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Therefore, also unlike most previous investigators, we
converted eGFR to milliliters per minute using the Du
Bois formula for BSA in order to remove the 1.73 m2
normalization factor [12,37]. The current models could be
used to develop dosing algorithms that include eGFR, de-
sired interval, and trough goal. If serum cystatin C levels
are not available at therapy initiation, we suggest that ini-
tial recommendations could use the eGFRcreatinine model
(model 5) with subsequent dose modification based on
the eGFRcreatinine-cystatin C model (model 7) once available.
The exact reason why serum cystatin C performed bet-
ter than serum creatinine for vancomycin trough predic-
tion is not entirely clear. Numerous studies among
stable ambulatory patients have shown that cystatin C-
based equations perform similar to creatinine-based
equations in estimating GFR when either marker is used
in isolation [12,20,21]. However, cystatin C may more
closely capture subtle fluctuations in GFR among acutely
ill, hospitalized patients than serum creatinine [42]. In-
flammation is an important non-GFR determinant of in-
creased cystatin C levels [43,44]. In the hospital setting,
rises in cystatin C could reflect inflammation second-
ary to infection, and the severity of infection, hence
an increase in cystatin C, may predict a GFR decline
which ultimately impacts vancomycin trough levels.
The 15 mL/min lower GFR estimate by CKD-EPIcystatin C
than by CKD-EPIcreatinine is consistent with both hypoth-
eses. In addition, the biggest improvement in troughs was
among individuals with higher levels of GFR, a group in
whom cystatin C appears to perform better than creatin-
ine alone as a biomarker of GFR [12]. We also found thatGFR estimation may not actually be a necessary step for a
vancomycin dosing model. Models 2 and 3 use cystatin C
without estimating GFR and perform similar to models 6
and 7. Furthermore, models 2 and 3 do not rely on the
documentation of height. Given the historical reliance on
GFR estimating equations for drug dosing, models using
eGFR may be easier to implement in clinical practice.
There are several potential limitations of this study.
The small proportion of non-Caucasian individuals in-
cluded does not allow study of the impact that race and
ethnicity could have on model performance. However,
cystatin C GFR estimates have not been found to be sig-
nificantly impacted by race, and the performance of the
CKD-EPI equations in Caucasian populations has been
established [12]. In addition, few patients in the present
study were experiencing significant changes in renal
function based upon serum creatinine at the time of in-
clusion. However, patients clearly developing AKI would
not be dosed on a consistent schedule but instead would
be dosed individually based upon random vancomycin
levels. Indeed, any dosing algorithm will need to be sus-
pended if the patient develops AKI. Patients with a body
mass index of more than 32 kg/m2 were also excluded.
Obesity alters the pharmacokinetics of vancomycin and
affects cystatin C levels independent of GFR, and thus
the performance of cystatin C-based dosing models in
this population needs further study [34,43]. We
emphasize that prospective testing of these models is
needed to determine whether the expected improve-
ment can be translated into actual improvement in tar-
get trough achievement. Also, though not the subject of
the present study, future research should also evaluate
whether any change in actual vancomycin target attain-
ment with cystatin C-based dosing algorithms translates
into improvements in therapeutic efficacy and safety.
Conclusions
We found that a model based on eGFR from CKD-
EPIcreatinine-cystatin C optimally predicts vancomycin
trough levels. Target trough achievement (10 to 15 mg/L
or 15 to 20 mg/L) is expected to be about 2.5-fold better
with this model than current clinical practice. These
findings are promising and encourage further investiga-
tion to prospectively validate the proposed or similar
cystatin C-based vancomycin dosing models.
Key messages
 Vancomycin dosing in hospitalized adults
infrequently achieves recommended target trough
levels, perhaps due to suboptimal assessment of
glomerular filtration rate.
 A novel cystatin C-based dosing model which includes
eGFR with the CKD-EPIcreatinine-cystatin C equation was
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improvement in target trough attainment over
usual care.
 Cystatin C is a promising GFR surrogate and further
study is needed to evaluate its potential for
medication dosing.
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